URSOBIL 250 mg price in UAE

Overview

Welcome to Dwaey, specifically on URSOBIL 250 mg Capsules (Hard Gelatin) page.
This medicine contains an important and useful components, as it consists of Ursodeoxycholic acid.
URSOBIL 250 mg is available in the market in concentration 250 mg/Capsule and in the form of Capsules (Hard Gelatin).

ABC FARMACEUTICI S.P.A is the producer of URSOBIL 250 mg and it is imported from ITALY, The most popular alternatives of URSOBIL 250 mg are listed downward .

Mode Of Action

Ursodeoxycholic acid suppresses hepatic synthesis and secretion of cholesterol and also inhibits intestinal absorption of cholesterol.

Indication

Dissolution of cholesterol-rich gallstones
Primary biliary cirrhosis
Prevention of gallstones

Precaution

50% of successfully treated patients will develop further gallstones within 10 yr. Pregnancy and lactation. Monitoring Parameters Monitor LFTs mthly for the 1st 3 mth and every 6 mth thereafter. Lactation: unknown if excreted in breast milk; use caution

Side Effects

>10% Headache
Dizziness
Diarrhea
Dyspepsia
Nausea/vomiting
Back pain
Upper respiratory tract infection 1-10% Alopecia
Rash
Hyperglycemia
Flatulence
Peptic ulcer
Urinary tract infection
Leukopenia
Thrombocytopenia
Cholecystitis >1% Fatigue
Abdominal pain
Thrombocytopenia
Pruritus
Angioedema
Peripheral edema
Biliary pain

Contra indication

Acute inflammation of gallbladder or biliary tract, occlusion of biliary tract, frequent episodes of biliary colic, radio-opaque calcified gallstones, impaired contractility of gallbladder, non-functioning gallbladder, inflammatory bowel disease, hepatic and intestinal conditions interfering w/ enterohepatic recirculation of bile acids, extrahepatic and intrahepatic cholestasis, ileal resection and stoma, regional ileitis, active duodenal and gastric ulcer; acute, chronic or severe hepatic disease.

Pregnancy and lactation

Pregnancy category: B

Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

Interaction

Cholestyramine, charcoal and antacids may reduce effectiveness. Aluminum-based antacids may reduce absorption. Oestrogens and clofibrate may counteract effectiveness of ursodeoxycholic acid by increasing cholesterol elimination in bile. Possible increase in ciclosporin serum concentration. Decreased effectiveness of dapsone. Possible decrease in serum ciprofloxacin and nitrendipine.